Apollo Hospitals Q2 FY27 Results: Profit Up, Divestment Complete, Management Changes
Apollo Hospitals reported Q2 FY27 results with a profit after tax of ₹4,757 million. Dr. Madhu Sasidhar ceased as President & CEO, and Dr. Ritu Garg was appointed CEO, Multi Regions. The divestment of subsidiaries to KCIL for ~₹11,500 million is complete. The company is advancing its composite scheme of arrangement.
The financial results show improved profitability. The completion of a major divestment and ongoing corporate restructuring (scheme of arrangement) have significant implications for the company's future structure and financial performance. Key management changes also contribute to a high impact.
The company reported an increase in profit after tax for the quarter and half-year ended September 30, 2026, and has successfully completed a significant divestment transaction, indicating positive operational and strategic progress.
Apollo Hospitals Enterprise Limited announced its unaudited financial results for the three and six months ended September 30, 2026. The Board of Directors approved these results, which have been subjected to a limited review by the statutory auditors.
The company also reported the cessation of Dr. Madhu Sasidhar as President & CEO - Hospitals Division and Senior Managerial Personnel, effective November 14, 2026, due to the completion of his employment tenure. Dr. Ritu Garg has been appointed as Chief Executive Officer, Multi Regions.
Furthermore, the divestment by Apollo Health and Lifestyle Limited (AHLL), a wholly-owned subsidiary, of its entire shareholding in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited (KCIL) has been completed on November 3, 2026. AHLL received the agreed consideration and was allotted securities representing approximately a 9.9% equity stake in KCIL. The transaction was valued at approximately ₹11,500 million, comprising cash consideration of ₹7,650 million and an equity stake in KCIL valued at ₹3,850 million.
The financial results indicate a profit after tax of ₹4,757 million for the three months ended September 30, 2026, compared to ₹3,852 million in the same period last year. For the six months ended September 30, 2026, the profit after tax stood at ₹8,607 million, up from ₹7,268 million in the corresponding period of the previous year. The company also reported an EBITA of ₹7,226 million for the three months ended September 30, 2026.
The company is progressing with its Composite Scheme of Arrangement, which includes the demerger of its Omni channel pharmacy distribution and digital health platform businesses, followed by amalgamations. The scheme has received necessary approvals from creditors and shareholders, and a petition has been filed with the National Company Law Tribunal for sanction.
What to do with a filing like this
Apollo Hospitals Enterprise Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Apollo Hospitals Enterprise Limited. Read the original for the full detail.